Psychoses: A primary care perspective

Medical Journal of Australia

Volumn 168, Issue 3, 1998, Pages 129-135

  Copolov, David L ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

AUTOIMMUNE DISEASE; DRUG ABUSE; ENDOCRINE DISEASE; GENERAL PRACTITIONER; HUMAN; METABOLIC DISORDER; NEUROLOGIC DISEASE; PATIENT CARE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; REVIEW; SCREENING; SYMPTOM; COMPARATIVE STUDY; GENERAL PRACTICE; METHODOLOGY; PREVALENCE;

FAMILY PRACTICE; HUMANS; PREVALENCE; PSYCHOTIC DISORDERS;

EID: 0032472421     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1998.tb126750.x     Document Type: Review

References (49)

1. Working Party Concerning General Practice & Victorian Mental Health Services, The Royal Australian College of General Practitioners Victoria Faculty. All things to all people - the general practitioner as provider of mental health care. Melbourne: RACGP, 1995.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press Inc., 1994.
3. World Health Organization. International classification of diseases. 10th ed. Geneva: World Health Organization, 1994.
4. Samson JA, Simpson JC, Tsuang MT. Outcome studies of schizoaffective disorder. Schizophr Bull 1988; 14: 543-554.
5. Lapensee M. A review of schizoaffective disorder: II somatic treatment. Can J Psychiatry, 1992; 37: 347-349.
6. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health organisation ten-country study. Psychol Med Monogr Suppl 1992; 20: 29-31.
7. Regier DA, Boyd JH, Burke JD, et al. One-month prevalence of mental disorders in the United States. Arch Gen Psychiatry 1988; 45: 977-986.
8. Tien AY, Eaton WW. Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome. Arch Gen Psychiatry; 1992, 49: 37-46.
9. Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry 1991; 48: 1075-1081.
10. Goodwin FK, Jamison KR. Manic-depressive illness. New York, NY: Oxford University Press; 1990.
11. Lewis SW. The secondary schizophrenias. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford. Blackwell Science, 1995: 324-340.
12. McClellan RL, Eisenberg RL, Giyanani VL. Routine CT screening of psychiatry inpatients. Radiology 1988; 169(1): 99-100.
13. Lewis S, Flint J. The differentiation of organic and functional psychoses. In: Barnes TR, Nelson HE. The assessment of psychoses. London: Chapman & Hall Medical, 1994; 173-190.
14. Weinberger DR. Brain disease and psychiatric illness: When should a psychiatrist order a CAT scan? Am J Psychiatry 1984; 141: 1521-1527.
15. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483-1486.
16. De Quardo JR, Carpenter CF, Tandon R. Patterns of substance abuse in schizophrenia: nature and significance. J Psychiat Res 1994; 28: 267-275.
17. Safer DJ. Substance abuse by young adult chronic patients. Hosp Community Psychiatry 1987; 38: 511-514.
18. Test MA, Wallisch LS, Allness DL, Ripp K. Substance use in young adults with schizophrenia disorders. Schizophr Bull 1989; 15: 465-476.
19. Loebel A, Lieberman JA, Alvir JM, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149: 1183-1188.
20. Hambrecht M, Hafner H, Löffler W. Beginning schizophrenia observed by significant others. Soc Psychiatry Psychiatr Epidemiol 1994; 29: 53-60.
21. Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry 1996; 30: 587-599.
22. McGorry PD, Edwards J, Mihalopoulos C, et al. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 1996; 22(2): 305-326.
23. McNamara K, Lewin T. General practitioners' recognition and management of psychiatric illness. Med J Aust 1989; 151: 250-257.
24. Nazareth I, King M, Haines A, et al. Care of schizophrenia in general practice. BMJ 1993; 307: 910.
25. Saugstad LF, Ödegaard Ö. Mortality in psychiatric hospitals in Norway 1950-74. Acta Psych Scand 1979; 59: 431-447.
26. Gopalaswamy AK, Morgan R. Smoking in chronic schizophrenia. Brit J Psychiatry 1986; 149: 523.
27. Farmer S. Medical problems of chronic patients in a community support program. Hosp Community Psychiatry 1988; 38: 745-749.
28. Keks N, Alston B, Sacks T, et al. Collaboration between general practice and community psychiatric services for people with chronic mental illness. Med J Aust 1997; 167: 266-271.
29. Meadows G. Establishing a collaborative service model for primary health care. Med J Aust 1998. In press.
30. Van Putten T, Marshall BD, Liberman R, et al. Systematic dosage reduction in treatment-resistant schizophrenic patients. Psychopharmacol Bull 1993; 29: 315-320.
31. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of pyschoses. Arch Gen Psychiatry 1988; 45: 79-90.
32. Salzman C, Green AI, Rodriguez-Villa F, et al. Benzodiazepines combined with neuroleptics for management of severe disruptive behaviour. Psychosomatics 1986; 27: 17-21.
33. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In: Hirch SR, Weinberger DR (editors). Schizophrenia. Oxford. Blackwell Science, 1995; 546-565.
34. Schatzberg AF, Cole JO, DeBattista C. Antipsychotic drugs. Manual of clinical psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Press, 1997; 113-180.
35. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Washington, DC: American Psychiatric Press, 1997.
36. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
37. Copolov D, Bell R, Benson W, et al. Clozapine treatment in Australia - a review of haematological monitoring. Med J Aust 1998. In press.
38. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992; 53: 426-433.
39. Psychotropic Drug Guidelines Subcommittee, Victorian Drug Usage Advisory Committee. Psychotropic drug guidelines. 4th ed. Melbourne: Victorian Postgraduate Medical Foundation, 1997. Third edition, 1995.
40. McElroy SL, Keck PE, Strakowski SM. Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996; 57(Suppl 3): 14-26.
41. Expert consensus guidelines. Treatment of bipolar disorder. J Clin Psychiatry 1996; 57(suppl 12A).
42. Victorian Drug Usage Advisory Committee. Therapeutic guidelines: neurology. Therapeutic Guidelines Limited, 1997.
43. Coryell W. Psychotic depression. J Clin Psychiatry 1996; 57(suppl 3): 27-31.
44. Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness: a comparison with lithium. Acta Psychiat Scand 1981; 64: 226-237.
45. Kane JM, Jeste DV, Barnes TRE, et al. Tardive dyskinesia: A task force report of the American Psychiatric Association. Washington DC: American Psychiatric Association, 1992.
46. Fink M. Who should get ECT? In: Coffey CE. The clinical science of electroconvulsive therapy. Washington DC: American Psychiatric Press; 1993: 3-17.
47. Coryell W, Zimmerman M. Outcome following ECT for primary unipolar depression: a test of newly proposed response predictors. Am J Psychiatry 1984; 141: 862-867.
48. Pande A, Krugler T, Haskett R, et al. Predictors of response to electroconvulsive therapy in major depressive disorder. Biol Psychiatry 1988; 24: 91-93.
49. Keck PE, McElroy EL, Strakowski SM, West SA. Pharmacologic treatment of schizoaffective disorder. Psychopharmacology (Berl) 1994; 114: 529-538.